Characterization of aliphatic, cyclic, and aromatic N-terminally "capped" His-D-Phe-Arg-Trp-NH2 tetrapeptides at the melanocortin receptors

European Journal of Pharmacology

Volumn 462, Issue 1-3, 2003, Pages 41-52

  Holder, Jerry Ryan ^a   Marques, Fernanda F ^a   Xiang, Zhimin ^a   Bauzo, Rayna M ^a   Haskell Luevano, Carrie ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

G protein coupled receptor; Melanocortin receptor; Melanotropin; Obesity

Indexed keywords

ALIPHATIC COMPOUND; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; AROMATIC COMPOUND; HISTIDYLPHENYLALANYLARGINYLTRYPTOPHANAMIDE; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; MELANOCORTIN RECEPTOR; PEPTIDE DERIVATIVE; PHENYL GROUP; TETRAPEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; EMBRYO; FEEDING BEHAVIOR; HUMAN; HUMAN CELL; OBESITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

EID: 0037458720     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01322-0     Document Type: Article

References (57)

1. Adan R.A.H., Gispen W.H. Melanocortins and the brain: from effects via receptors to drug targets. Eur. J. Pharmacol. 405:2000;13-24.
2. Adan R.A.H., Szklarczyk A.W., Oosterom J., Brakkee J.H., Nijenhuis W.A.J., Schaaper W.M.M., Meloen R.H., Gispen W.H. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur. J. Pharmacol. 378:1999;249-258.
3. Al-Obeidi F., Castrucci A.M.D., Hadley M.E., Hruby V.J. Potent and prolonged acting cyclic lactam analogs of α-melanotropin-design based on molecular-dynamics. J. Med. Chem. 32:1989;2555-2561.
4. Al-Obeidi F., Hruby V.J., Castrucci A.M., Hadley M.E. Design of potent linear α-melanotropin 4-10 analogues modified in positions 5 and 10. J. Med. Chem. 32:1989;174-179.
5. Al-Obeidi F., Hruby V.J., Hadley M.E., Sawyer T.K., Castrucci A.M. Design, synthesis, and biological activities of a potent and selective α-melanotropin antagonist. Int. J. Pept. Protein Res. 35:1990;228-234.
6. Al-Obeidi F., Hruby V.J., Yaghoubi N., Marwan M.M., Hadley M.E. Synthesis and biological activities of fatty acid conjugates of a cyclic lactam α-melanotropin. J. Med. Chem. 35:1992;118-123.
7. Benoit S.C., Schwartz M.W., Lachey J.L., Hagan M.M., Rushing P.A., Blake K.A., Yagaloff K.A., Kurylko G., Franco L., Danhoo W., Seeley R.J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci. 20:2000;3442-3448.
8. Butler A.A., Cone R.D. Knockout models resulting in the development of obesity. Trends Genet. 17:2001;S50-S54.
9. Butler A.A., Kesterson R.A., Khong K., Cullen M.J., Pelleymounter M.A., Dekoning J., Baetscher M., Cone R.D. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology. 141:2000;3518-3521.
10. Carpino L.A., Han G.Y. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J. Am. Chem. Soc. 92:1970;5748-5749.
11. Carpino L.A., Han G.Y. 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 37:1972;3404-3405.
12. Castrucci A.M., Hadley M.E., Sawyer T.K., Hruby V.J. Enzymological studies of melanotropins. Comp. Biochem. Physiol., B. 78:1984;519-524.
13. Castrucci A.M.L., Hadley M.E., Sawyer T.K., Wilkes B.C., Alobeidi F., Staples D.J., Devaux A.E., Dym O., Hintz M.F., Riehm J.P., Rao K.R., Hruby V.J. α-Melanotropin - the minimal active sequence in the lizard skin bioassay. Gen. Comp. Endocrinol. 73:1989;157-163.
14. Chaturvedi D.N., Knittel J.J., Hruby V.J., Castrucci A.M.D., Hadley M.E. Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins. J. Med. Chem. 27:1984;1406-1410.
15. 7]-α-MSH. J. Pharm. Sci. 74:1985;237-240.
16. q-coupled signaling pathways. Anal. Biochem. 226:1995;349-354.
17. Chen W.B., Kelly M.A., OpitzAraya X., Thomas R.E., Low M.J., Cone R.D. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 91:1997;789-798.
18. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., Rosenblum C.I., Vongs A., Feng Y., Cao L.H., Metzger J.M., Strack A.M., Camacho R.E., Mellin T.N., Nunes C.N., Min W., Fisher J., Gopal-Truter S., MacIntyre D.E., Chen H.Y., Van der Ploeg L.H.T. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26:2000;97-102.
19. Cone R.D., Lu D., Koppula S., Vage D.I., Klungland H., Boston B., Chen W., Orth D.N., Pouton C., Kesterson R.A. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog. Horm. Res. 51:1996;287-317. (discussion 318).
20. Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S., Horvath T.L., Cone R.D., Low M.J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 411:2001;480-484.
21. Danho W., Swistok J., Cheung A., Chu X.-J., Wang Y., Chen L., Bartkovitz D., Gore V., Qi L., Fry D., Greeley D., Sun H., Guenot J., Franco L., Kurylko G., Rumennik L., Yagaloff K. Highly selective cyclic peptides for human melanocortin-4 receptor: design, synthesis, bioactive conformation, and pharmacological evaluation as an anti-obesity agent. Lebl M., Houghten R.A. Peptides: The Wave of the Future: Proceedings of the Second International and the Seventeenth American Peptide Symposium. 2001;701-704 Kluwer Academic Publishing, Norwell, MA.
22. De Wied D. Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. Eur. J. Pharmacol. 375:1999;1-11.
23. Eberle A.N. The Melanotropins: Chemistry, Physiology, and Mechanism of Action. 1988;Karger, Basel.
24. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 385:1997;165-168.
25. Hadley M.E. The Melanotropic Peptides: Source, Synthesis, Chemistry, Secretion and Metabolism. 1989;CRC Press, Boca Raton, FL.
26. Hadley M.E., Al-Obeidi F., Hruby V.J., Weinrach J.C., Freedberg D., Jiang J.W., Stover R.S. Biological activities of melanotropic peptide fatty acid conjugates. Pigment Cell Res. 4:1991;180-185.
27. Haskell-Luevano C. In vitro mutagenesis studies of melanocortin receptor coupling and ligand binding. Cone R.D. The Melanocortin Receptors. 2000;263-306 Humana Press, Totowa, NJ.
28. Haskell-Luevano C., Sawyer T.K., Hendrata S., North C., Panahinia L., Stum M., Staples D.J., Castrucci A.M.D., Hadley M.E., Hruby V.J. Truncation studies of α-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides. 17:1996;995-1002.
29. Haskell-Luevano C., Sawyer T.K., Trumpp-Kallmeyer S., Bikker J.A., Humblet C., Gantz I., Hruby V.J. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Drug Des. Discov. 14:1996;197-211.
30. Haskell-Luevano C., Cone R.D., Monck E.K., Wan Y.P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry. 40:2001;6164-6179.
31. Haskell-Luevano C., Holder J.R., Monck E.K., Bauzo R.M. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors. J. Med. Chem. 44:2001;2247-2252.
32. 2 at the mouse melanocortin receptors: 1. Modifications at the His position. J. Med. Chem. 45:2002;2801-2810.
33. 2 at the mouse melanocortin receptors: Part 2. Modification at the Phe position. J. Med. Chem. 45:2002;3073-3081.
34. Hruby V.J., Wilkes B.C., Hadley M.E., Alobeidi F., Sawyer T.K., Staples D.J., Devaux A.E., Dym O., Castrucci A.M.D., Hintz M.F., Riehm J.P., Rao K.R. α-Melanotropin - the minimal active sequence in the frog-skin bioassay. J. Med. Chem. 30:1987;2126-2130.
35. Hruby V.J., Sharma S.D., Toth K., Jaw J.Y., Al-Obeidi F., Sawyer T.K., Hadley M.E. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann. N.Y. Acad. Sci. 680:1993;51-63.
36. Hruby V.J., Li G., Haskell-Luevano C., Shenderovich M. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers. 43:1997;219-266.
37. Huszar D., Lynch C.A., FairchildHuntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141.
38. Kaiser E., Colescot R.L., Bossinge C.D., Cook P.I. Color test for detection of free terminal amino groups in solid-phase synthesis of peptides. Anal. Biochem. 34:1970;595-598.
39. Kask A., Pahkla R., Irs A., Rago L., Wikberg J.E.S., Schioth H.B. Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. NeuroReport. 10:1999;707-711.
40. Lerner A.B., McGuire J.S. Effect of α- and β-melanocyte stimulating hormones on skin colour of man. Nature. 189:1961;176.
41. Lu D.S., Willard D., Patel I.R., Kadwell S., Overton L., Kost T., Luther M., Chen W.B., Woychik R.P., Wilkison W.O., Cone R.D. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature. 371:1994;799-802.
42. Lu D., Haskell-Luevano C., Väge D.I., Väge R.D., Väge C. Functional variants of the MSH receptor (MC1-R), agouti, and their effects on mammalian pigmentation. Spiegel A.M. G-Proteins, Receptors, and Disease. 1997;231-259 Humana Press, Totowa, NJ.
43. Lu D., Väge D.I., Väge R.D., Väge C. A ligand-mimetic model for constitutive activation of the melanocortin-1 receptor. Mol. Endocrinol. 12:1998;592-604.
44. MacNeil D.J., Howard A.D., Guan X.M., Fong T.M., Nargund R.P., Bednarek M.A., Goulet M.T., Weinberg D.H., Strack A.M., Marsh D.J., Chen H.Y., Shen C.P., Chen A.R.S., Rosenblum C.I., MacNeil T., Tota M., MacIntyre E.D., Van der Ploeg L.H.T. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. J. Pharmacol. 440:2002;141-157.
45. 4 receptors increases erectile activity in rats ex copula. Eur. J. Pharmacol. 454:2002;71-79.
46. Mountjoy K.G., Robbins L.S., Mortrud M.T., Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science. 257:1992;1248-1251.
47. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., Barsh G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. [published erratum appears in Science 1998 Sep. 11;281(5383):1615] Science. 278:1997;135-138.
48. Sargent D.F., Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5774-5778.
49. Shutter J.R., Graham M., Kinsey A.C., Scully S., Luthy R., Stark K.L. Hypothalamic expression of art, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 11:1997;593-602.
50. Van der Kraan M., Adan R.A.H., Entwistle M.L., Gispen W.H., Burbach J.P.H., Tatro J.B. Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology. 139:1998;2348-2355.
51. Van der Ploeg L.H., Martin W.J., Howard A.D., Nargund R.P., Austin C.P., Guan X., Drisko J., Cashen D., Sebhat I., Patchett A.A., Figueroa D.J., DiLella A.G., Connolly B.M., Weinberg D.H., Tan C.P., Palyha O.C., Pong S.S., MacNeil T., Rosenblum C., Vongs A., Tang R., Yu H., Sailer A.W., Fong T.M., Huang C., Tota M.R., Chang R.S., Stearns R., Tamvakopoulos C., Christ G., Drazen D.L., Spar B.D., Nelson R.J., MacIntyre D.E. A role for the melanocortin 4 receptor in sexual function. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11381-11386.
52. Vergoni A.V., Bertolini A. Role of melanocortins in the central control of feeding. Eur. J. Pharmacol. 405:2000;25-32.
53. Vergoni A.V., Bertolini A., Mutulis F., Wikberg J.E.S., Schioth H.B. Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats. Eur. J. Pharmacol. 362:1998;95-101.
54. Vergoni A.V., Bertolini A., Guidetti G., Karefilakis V., Filaferro M., Wikberg J.E.S., Schioth H.B. Chronic melanocortin 4 receptor blockage causes obesity without influencing sexual behavior in male rats. J. Endocrinol. 166:2000;419-426.
55. Vrinten D.H., Kalkman C.J., Adan R.A., Gispen W.H. Neuropathic pain: a possible role for the melanocortin system? Eur. J. Pharmacol. 429:2001;61-69.
56. 7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J. Biol. Chem. 272:1997;23000-23010.
57. Yang Y.K., Fong T.M., Dickinson C.J., Mao C., Li J.Y., Tota M.R., Mosley R., Van Der Ploeg L.H., Gantz I. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 39:2000;14900-14911.